Abstract
Background Vaccination with live attenuated SIV confers potent protection against wild-type challenge, although correlates of adaptive immunity have not been reliably demonstrated. Despite safety concerns for this vaccine approach in humans, understanding the mechanism of this protection may inform and guide HIV vaccine design. In Mauritian-origin cynomolgus macaques (Macaca fascicularis), we have demonstrated early, potent protection against the heterologous SIVsmE660 virus stock following vaccination with the minimally attenuated SIVmac251/C8 vaccine [1]. Failure to associate correlates of protection with adaptive immune responses and the emergence of protection as early as 3 weeks post vaccination has led us to characterise antiretroviral innate immune responses in this model system.
Highlights
Vaccination with live attenuated SIV confers potent protection against wild-type challenge, correlates of adaptive immunity have not been reliably demonstrated
To evaluate aspects of the innate immune response, TRIM5a genotype was determined and transcriptome analysis performed by quantitative PCR (qPCR) for multiple ínterferon-inducing and induced genes including IRF-7, STAT-1, TRIM5a, 1HPA-NIBSC, Division of Retrovirology, Potters Bar, Herts, UK Full list of author information is available at the end of the article
Following SIV inoculation, rapid and widespread dissemination of virus was identified in multiple lymphoid tissues
Summary
Vaccination with live attenuated SIV confers potent protection against wild-type challenge, correlates of adaptive immunity have not been reliably demonstrated. Despite safety concerns for this vaccine approach in humans, understanding the mechanism of this protection may inform and guide HIV vaccine design. In Mauritian-origin cynomolgus macaques (Macaca fascicularis), we have demonstrated early, potent protection against the heterologous SIVsmE660 virus stock following vaccination with the minimally attenuated SIVmac251/C8 vaccine [1]. Failure to associate correlates of protection with adaptive immune responses and the emergence of protection as early as 3 weeks post vaccination has led us to characterise antiretroviral innate immune responses in this model system
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
